All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Powering insights from Cortellis. Link to Cortellis page on Clarivate website.
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing the state of COVID-19 testing
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, January 16, 2021
See today's BioWorld
Home » IO Biotech fuels immuno-oncology resurgence with $155M series B round
To read the full story, subscribe or sign in.

IO Biotech fuels immuno-oncology resurgence with $155M series B round

Last updated: Jan. 13, 2021
By Cormac Sheridan
No Comments
Dublin – IO Biotech ApS raised €127 million (US$154.7 million) in a series B round to fund a potentially pivotal trial of its combination of cancer vaccines in first-line metastatic melanoma. The Copenhagen, Denmark-based company is one of a number of firms fueling a mini-resurgence in immuno-oncology in the early weeks of the new year, as new data and new insights are prompting additional investments in an area that some had thought was already oversubscribed.
BioWorld Financings Cancer Immuno-oncology Series B

Popular Stories

  • British flag

    Accuracy, utility of COVID-19 lateral flow tests questioned in the U.K.

    BioWorld MedTech
    LONDON – A huge row has broken out in the U.K. about the accuracy and utility of COVID-19 lateral flow tests (LFT) in screening asymptomatic people, as a pilot...
  • Total artificial heart being manufactured

    Carmat's artificial heart receives CE mark

    BioWorld MedTech
    Carmat SA said its total artificial heart received the CE mark, and the company plans to ramp up production to enable the launch of the device in the second...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan. 15.
  • Israeli flag

    Israel continues to shine as hub of med-tech innovation

    BioWorld MedTech
    In recent years, Israel has proven to be a hot spot for med-tech innovation. The country boasts more than 1,500 companies in the health care and life sciences...
  • Doctor examining child in wheelchair

    Sarepta DMD phase II hangs in ‘balance’ as disparity in North Star leads astray

    BioWorld
    Sarepta Therapeutics Inc.’s miss on a key phase II ambulatory endpoint in its Duchenne muscular dystrophy (DMD) trial may have been caused by a dramatic disparity...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing